Non-drug thérapies for Alzheimer's patients

EHP 2000;6(2):64-68 Alternative Approaches to the Economic Evaluation of a Drug for Patients with Alzheimers Disease

The increasing prevalence of Alzheimer’s Disease (AD), and the costs of the drugs emerging for its treatment, together pose the question of how to evaluate these drugs in economic terms. We examine two approaches, first, an outline proposal [1] examining the requirements of a cost-effectiveness analysis of AD drugs; as it is defined, there exist severe problems in the areas of quality of life m...

Does Fungal Infection Cause Alzheimers?

Current State of Alzheimers Disease Research Therapeutics

1

Magnesium and Alzheimers Disease: The Cholinergic Hypothesis

The cholinergic deficit in Alzheimer’s disease (AD) remains the cornerstone for the understanding of chemical signal transfer. Hypofunctions of cholinergic systems are significantly involved in the signs and symptoms of senile dementia of the Alzheimer type. Cognitive deficits in AD have been widely associated with dysfunction of the cholinergic system. As a diagnostic marker of AD the activity...

Alzheimers Disease: Review of Emerging Treatment Role for Intravenous Immunoglobulins

Alzheimer's disease (AD) is the most common neurodegenerative disorder. Currently available therapies are symptomatic but do not alter underlying disease progression. Immunotherapeutic approaches such as anti Aβ peptide active vaccination trials have had limited success to date. Intravenous immunoblobulin (IVIg) is widely used in immune-mediated neurological disorders such myasthenia gravis and...